Clinical Trials Directory

Trials / Completed

CompletedNCT01674088

Sucrose Breath Test to Determine Intestinal Permeability in IBS

The Use of a Novel 13C Sucrose Breath Test (13C SBT) to Determine Intestinal Permeability in Irritable Bowel Syndrome (IBS) Patients

Status
Completed
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Metabolic Solutions Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Irritable Bowel Syndrome (IBS) is a growing clinical diagnosis affecting 10-20% of the US population. While current diagnostic criteria aids in correctly diagnosing IBS, the cause of the disease still remains unclear. It has been hypothesized that patients with IBS have alterations in the intestinal lining leading to release of toxic substances into the blood, commonly referred to as leaky gut. Current methods used to study leaky gut are both expensive and invasive. The investigators will test a new breath test to measure leaky gut in both IBS patients and subjects without IBS symptoms.

Detailed description

The sucrose breath test involves taking by mouth 20 grams of common sucrose. This amount of sucrose is about 4 packets of sugar that you would use to sweeten a beverage. If subjects meet eligibility criteria, a single breath test will be conducted on all subjects. The breath test involves collecting breath by exhaling through a straw into a special test tube. A breath sample is collected before administration of sucrose. After the baseline breath sample, a sugar solution with the 20 grams of sucrose is administered by mouth. Three additional breath samples are collected at 30, 60 and 90 minutes. After 90 minutes, the protocol is finished. We will be analyzing breath carbon dioxide for different levels of heavy carbon atoms (carbon-13)with an instrument called an isotope ratio mass spectrometer. Our study plan is to compare the amount of carbon-13 in breath between IBS patients and subjects without the condition. Up to 20 subjects per group will be studied.

Conditions

Timeline

Start date
2012-10-01
Primary completion
2012-12-01
Completion
2013-01-01
First posted
2012-08-28
Last updated
2014-02-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01674088. Inclusion in this directory is not an endorsement.